NZ735052A - Therapeutic antibodies and their uses - Google Patents

Therapeutic antibodies and their uses

Info

Publication number
NZ735052A
NZ735052A NZ735052A NZ73505216A NZ735052A NZ 735052 A NZ735052 A NZ 735052A NZ 735052 A NZ735052 A NZ 735052A NZ 73505216 A NZ73505216 A NZ 73505216A NZ 735052 A NZ735052 A NZ 735052A
Authority
NZ
New Zealand
Prior art keywords
lymphoma
seq
cell
sequence shown
region
Prior art date
Application number
NZ735052A
Other versions
NZ735052B2 (en
Inventor
Arvind Rajpal
Blarcom Thomas Van
Tracy Chia-Chien Kuo
Riggers Javier Fernando Chaparro
Wei Chen
Amy Shaw-Ru Chen
Edward Derrick Pascua
Leila Marie Boustany
Yik Andy Yeung
Pavel Strop
Weihsien Ho
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55661497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ735052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Priority to NZ774327A priority Critical patent/NZ774327B2/en
Priority to NZ774326A priority patent/NZ774326B2/en
Publication of NZ735052A publication Critical patent/NZ735052A/en
Publication of NZ735052B2 publication Critical patent/NZ735052B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a bispecific antibody that specifically bind to BCMA (B­Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). The invention also relates to compositions comprising said bispecific antibody and methods of using the same for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease).

Claims (27)

Claims It is claimed:
1. A bispecific antibody comprising a first antibody variable domain that specifically binds to CD3 and a second antibody variable domain that specifically binds to BCMA, wherein a. the first antibody variable domain comprises a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 331, 332 or 333, (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 336 or 417; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342; and b. the second antibody variable domain comprises a heavy chain VH region comprising a heavy chain variable (VH) region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 151, 156, or 157; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 158 OR 159; and (iii) a VH CDR3 comprising SEQ ID NO: 155; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 209; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 221; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 225.
2. The bispecific antibody of claim 1, wherein the first antibody variable domain comprises a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising the sequence shown in SEQ ID NO: 332, (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 417; and iii) a VH CDR3 comprising the sequence shown in SEQ ID NO: 335; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 343; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 341; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 342; and the second antibody 5 10 15 20 25 variable domain comprises a heavy chain VH region comprising a heavy chain variable (VH) region comprising (i) a VH CDR1 comprising the sequence shown in SEQ ID NO: 151; (ii) a VH CDR2 comprising the sequence shown in SEQ ID NO: 159; and (iii) a VH CDR3 comprising SEQ ID NO: 155; and a light chain variable (VL) region comprising (i) a VL CDR1 comprising the sequence shown in SEQ ID NO: 209; (ii) a VL CDR2 comprising the sequence shown in SEQ ID NO: 221; and (iii) a VL CDR3 comprising the sequence shown in SEQ ID NO: 225.
3. The bispecific antibody of claim 1 or 2, wherein the first antibody variable domain comprises a heavy chain variable (VH) region comprising the sequence shown in SEQ ID NO: 324; and a light chain variable (VL) region comprising the sequence shown in SEQ ID NO: 323.
4. The bispecific antibody of any one of claims 1 to 3, wherein the second antibody variable domain comprises a heavy chain variable (VH) region comprising the sequence shown in SEQ ID NO: 112; and a light chain variable (VL) region comprising the sequence shown in SEQ ID NO: 38.
5. The bispecifc antibody of any one of claim 1 to 4, wherein the the first antibody variable domain comprises a heavy chain variable (VH) region comprising the sequence shown in SEQ ID NO: 324; and a light chain variable (VL) region comprising the sequence shown in SEQ ID NO: 323; and wherein the second antibody variable domain comprises a heavy chain variable (VH) region comprising the sequence shown in SEQ ID NO: 112; and a light chain variable (VL) region comprising the sequence shown in SEQ ID NO: 38.
6. A bispecific antibody comprising a first antibody variable domain that specifically binds to CD3 and a second antibody variable domain that specifically binds to BCMA, wherein the first antibody variable domain comprises: a heavy chain variable (VH) region comprising the sequence shown in SEQ ID NO: 324; and a light chain variable (VL) region comprising the sequence shown in SEQ ID NO: 323; and the second antibody variable domain comprises: a heavy chain variable (VH) region encoded by a nucleic acid molecule comprising the nucleotide sequence: 5 10 15 20 25 GAAGTCCAACTCCTCGAATCCGGTGGCGGCCTTGTCCAGCCTGGAGGTTC CTTGCGCCTGTCATGTGCCGCCAGCGGATTCACCTTCTCGTCCTACCCGAT GTCGTGGGTCCGCCAGGCTCCGGGAAAGGGCCTGGAATGGGTGTCAGCC ATCGGAGGATCGGGGGGCTCCCTGCCCTACGCCGATATCGTGAAGGGAAG GTTCACCATTAGCCGGGACAACTCCAAGAACACTCTGTACCTCCAAATGAA CAGCCTGAGAGCGGAGGACACCGCAGTGTACTATTGCGCCCGGTACTGGC CAATGGACATCTGGGGCCAGGGGACTCTGGTCACCGTCTCCTCA; and a light chain variable (VL) region encoded by a nucleic acid molecule comprising the nucleotide sequence: GAGATCGTGCTGACTCAGTCCCCTGGAACCCTGTCCCTGTCACCTGGCGAA AGAGCTACCTTGTCCTGTCGCGCATCACAATCCGTGTCGTCGAGCTATCTC GCGTGGTACCAGCAGAAGCCCGGACAGGCCCCAAGGCTGCTTATGTACGA CGCCTCCATCCGGGCCACTGGTATCCCCGACCGCTTCTCGGGCTCCGGAA GCGGCACCGACTTCACCCTGACTATTTCCCGGCTCGAACCGGAGGATTTCG CCGTGTACTACTGCCAACAGTACCAGAGCTGGCCGCTGACGTTTGGGCAG GGGACCAAGGTCGAAATCAAA.
7. The bispecific antibody of any one of claims 1-6, wherein the antibody comprises first and second respective human IgG2 constant regions comprising amino acid modifications at positions 223, 225, and 228, or 223 and 228, respectively, in the hinge region and at position 409 or 368 (EU numbering scheme), respectively, in the CH3 region of a human IgG2 (SEQ ID NO: 493).
8. The bispecific antibody of claim 7, further comprising an amino acid modification at position 265 of the human IgG2.
9. The bispecific antibody of claim 7 or 8, wherein the first constant region comprises the amino acid sequence of SEQ ID NO: 496.
10. The bispecific antibody of any one of claims 7 to 9, wherein the second constant region comprises the amino acid sequence of SEQ ID NO: 497.
11.
12.
13. A nucleic acid encoding the antibody of any one of claims 1-10. A vector comprising the nucleic acid of claim 11. A host cell comprising the nucleic acid of claim 11 or the vector of claim 12, provided that if the cell is a human cell it is ex vivo. 5 10 15 20 25 30
14. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 10.
15. The bispecific antibody of any one of claims 1-10, or the pharmaceutical composition of claim 14, for use as a medicament.
16. The bispecific antibody or pharmaceutical composition for use of claim 15, wherein the medicament is for use in treatment of a B-cell related cancer selecting from the group consisting of multiple myeloma, malignant plasma cell neoplasm, Hodgkin’s lymphoma, nodular lymphocyte predominant Hodgkin’s lymphoma, Kahler’s disease and Myelomatosis, plasma cell leukemia, plasmacytoma, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma, Burkitt’s lymphoma, marginal zone lymphoma, mantle cell lymphoma, large cell lymphoma, precursor B lymphoblastic lymphoma, myeloid leukemia, Waldenstrom’s macroglobulienemia, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, mucosa associated lymphatic tissue lymphoma, small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt lymphoma, primary mediastinal (thymic) large B-cell lymphoma, lymphoplasmactyic lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, T cell/histiocyte rich large B-cell lymphoma, primary central nervous system lymphoma, primary cutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated with inflammation, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and other B-cell related lymphoma.
17. 5 10 15 20 25 30 The bispecific antibody or pharmaceutical composition for use of claim 15, wherein the medicament is for use in treatment of multiple myeloma.
18. Use of a bispecific antibody of any one of claims 1-10 or the pharmaceutical composition of claim 14 in the manufacture of a medicament for treating a condition associated with malignant cells expressing a tumor antigen in a subject.
19. The use of claim 18, wherein the condition is a cancer.
20. The use of claim 19, wherein the cancer is a B-cell related cancer selecting from the group consisting of multiple myeloma, malignant plasma cell neoplasm, Hodgkin’s lymphoma, nodular lymphocyte predominant Hodgkin’s lymphoma, Kahler’s disease and Myelomatosis, plasma cell leukemia, plasmacytoma, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma, Burkitt’s lymphoma, marginal zone lymphoma, mantle cell lymphoma, large cell lymphoma, precursor B lymphoblastic lymphoma, myeloid leukemia, Waldenstrom’s macroglobulienemia, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, mucosa associated lymphatic tissue lymphoma, small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt lymphoma, primary mediastinal (thymic) large B-cell lymphoma, lymphoplasmactyic lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, T cell/histiocyte rich large B-cell lymphoma, primary central nervous system lymphoma, primary cutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated with inflammation, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and other B-cell related lymphoma. 5 10 15 20
21. Use of a bispecific antibody of any one of claims 1-10 or the pharmaceutical composition of claim 14 in the manufacture of a medicament for inhibiting tumor growth or progression in a subject who has malignant cells expressing BCMA.
22. Use of a bispecific antibody of any one of claims 1-10 or the pharmaceutical composition of claim 14 in the manufacture of a medicament for inhibiting metastasis of malignant cells expressing BCMA in a subject.
23. Use of a bispecific antibody of any one of claims 1-10 or the pharmaceutical composition of claim 14 in the manufacture of a medicament for inducing tumor regression in a subject who has malignant cells expressing BCMA.
24. Use of a bispecific antibody of any one of claims 1-10 or the pharmaceutical composition of claim 14 in the manufacture of a medicament for treating multiple myeloma in a subject in need thereof.
25. The use of claim 24, wherein the medicament is to be administered with one or more other therapeutic agents.
26. The use of claim 25, wherein the other therapeutic agent is selected from the group consisting of bortezomib, lenalidomide, carfilzomib, and doxorubicin.
27. The bispecific antibody of claim 1 or 6, substantially as herein described with reference to any one of the examples and/or
NZ735052A 2016-03-30 Therapeutic antibodies and their uses NZ735052B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ774327A NZ774327B2 (en) 2016-03-30 Therapeutic antibodies and their uses
NZ774326A NZ774326B2 (en) 2016-03-30 Therapeutic antibodies and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562146843P 2015-04-13 2015-04-13
US201562146504P 2015-04-13 2015-04-13
US201662301582P 2016-02-29 2016-02-29
PCT/IB2016/051801 WO2016166629A1 (en) 2015-04-13 2016-03-30 Therapeutic antibodies and their uses

Publications (2)

Publication Number Publication Date
NZ735052A true NZ735052A (en) 2025-03-28
NZ735052B2 NZ735052B2 (en) 2025-07-01

Family

ID=

Also Published As

Publication number Publication date
SA517390140B1 (en) 2021-11-24
AU2022203601B2 (en) 2025-07-10
PE20221262A1 (en) 2022-08-16
AU2016248946C1 (en) 2024-10-17
PH12023550222A1 (en) 2024-03-11
SG10201912819XA (en) 2020-02-27
IL254219A0 (en) 2017-10-31
HUS2400014I1 (en) 2024-06-28
PL3988117T3 (en) 2025-03-10
US11814435B2 (en) 2023-11-14
PT3988117T (en) 2025-01-23
KR20200053642A (en) 2020-05-18
NO2025024I1 (en) 2025-05-26
NO2026008I1 (en) 2026-02-19
FI4234581T3 (en) 2025-11-24
JP6913025B2 (en) 2021-08-04
ES3012402T3 (en) 2025-04-09
EP3283106B1 (en) 2021-12-22
CN114773476A (en) 2022-07-22
EP4234581B1 (en) 2025-09-17
CA3219680A1 (en) 2016-10-13
CN119708245A (en) 2025-03-28
HUE069499T2 (en) 2025-03-28
AU2016248946A1 (en) 2017-09-21
AU2022203620A1 (en) 2022-06-16
PL4234581T3 (en) 2026-01-26
HUS2500022I1 (en) 2025-06-28
EP3988117A1 (en) 2022-04-27
US20180171018A1 (en) 2018-06-21
IL310723A (en) 2024-04-01
FR26C1010I1 (en) 2026-04-17
CA2925329C (en) 2024-01-02
IL290496A (en) 2022-04-01
HUE057285T2 (en) 2022-04-28
NL301271I2 (en) 2026-02-17
FR24C1023I1 (en) 2024-07-26
PE20180046A1 (en) 2018-01-15
MX2022001830A (en) 2022-03-17
FR24C1023I2 (en) 2026-04-03
EP3988117B1 (en) 2024-11-27
HUE073610T2 (en) 2026-01-28
KR102110557B1 (en) 2020-05-15
MX2022001831A (en) 2022-03-17
CA3219665A1 (en) 2016-10-13
EP4647446A3 (en) 2026-02-18
CA3219684A1 (en) 2016-10-13
NZ774327A (en) 2025-03-28
WO2016166629A1 (en) 2016-10-20
SG11201707192XA (en) 2017-10-30
CN108136002A (en) 2018-06-08
BR112017019785B1 (en) 2022-11-16
ES3053863T3 (en) 2026-01-27
JP2021169486A (en) 2021-10-28
RU2017133826A3 (en) 2019-05-13
HRP20251284T1 (en) 2025-12-05
KR20200053641A (en) 2020-05-18
FI3988117T3 (en) 2025-01-27
PH12017501732A1 (en) 2018-04-02
US20180298108A1 (en) 2018-10-18
JP2023109898A (en) 2023-08-08
BR112017019785A2 (en) 2018-05-22
IL254219B (en) 2022-03-01
SG10201912823PA (en) 2020-02-27
TWI703157B (en) 2020-09-01
MY196625A (en) 2023-04-23
FIC20260009I1 (en) 2026-03-05
TWI787645B (en) 2022-12-21
AU2025248718A1 (en) 2025-10-30
PL3283106T3 (en) 2022-05-02
KR102405104B1 (en) 2022-06-07
LUC00344I1 (en) 2024-05-22
TW201706311A (en) 2017-02-16
CN114874331A (en) 2022-08-09
JP2018516068A (en) 2018-06-21
CO2017010495A2 (en) 2018-01-05
IL290488B1 (en) 2024-03-01
HK1255385A1 (en) 2019-08-16
ES2905315T3 (en) 2022-04-07
CN108136002B (en) 2022-05-31
US11155630B2 (en) 2021-10-26
CA2925329A1 (en) 2016-10-13
JP2025081581A (en) 2025-05-27
ZA201807153B (en) 2022-08-31
KR102405099B1 (en) 2022-06-07
SI4234581T1 (en) 2026-01-30
SI3988117T1 (en) 2025-03-31
US10793635B2 (en) 2020-10-06
JP2025081580A (en) 2025-05-27
EP4234581A3 (en) 2023-10-04
DK4234581T3 (en) 2025-10-06
RU2017133826A (en) 2019-05-13
US20210054087A1 (en) 2021-02-25
US20240018252A1 (en) 2024-01-18
FIC20250021I1 (en) 2025-05-27
PT3283106T (en) 2022-02-02
AU2016248946B2 (en) 2022-03-10
FIC20240014I1 (en) 2024-05-21
PT4234581T (en) 2025-11-18
TWI703159B (en) 2020-09-01
EP4647446A2 (en) 2025-11-12
US20160297885A1 (en) 2016-10-13
EP4234581A2 (en) 2023-08-30
LUC00344I2 (en) 2026-05-05
AU2022203620B2 (en) 2025-07-10
US9969809B2 (en) 2018-05-15
US10040860B2 (en) 2018-08-07
JP7641323B2 (en) 2025-03-06
DK3988117T3 (en) 2025-01-20
KR20170131699A (en) 2017-11-29
TW201811833A (en) 2018-04-01
IL310723B1 (en) 2026-07-01
EP3283106A1 (en) 2018-02-21
SI3283106T1 (en) 2022-04-29
NZ774326A (en) 2025-03-28
PE20221580A1 (en) 2022-10-06
FR25C1020I1 (en) 2025-08-01
IL290488B2 (en) 2024-07-01
HRP20241757T1 (en) 2025-02-28
IL290488A (en) 2022-04-01
TW202115120A (en) 2021-04-16
US20210188991A1 (en) 2021-06-24
MX2017013297A (en) 2018-06-19
DK3283106T3 (en) 2022-01-10
AU2022203601A1 (en) 2022-06-16
CN114874331B (en) 2025-01-07
RU2722381C2 (en) 2020-05-29
PH12023550223A1 (en) 2024-03-11
CN114773476B (en) 2025-09-09

Similar Documents

Publication Publication Date Title
FI3988117T3 (en) Therapeutic antibodies and their uses
RU2019138710A (en) ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS
RU2756010C2 (en) Combination of cd19 antibody and bruton tyrosine kinase inhibitor and their application
JP2020521481A5 (en)
US12194095B2 (en) Combinations and uses thereof
HRP20240149T1 (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
JP2020528750A5 (en)
ES2909720T3 (en) Combination therapy with an anti-CD19 antibody and a purine analog
US12358983B2 (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
JP2015532292A5 (en)
CN103732252B (en) Use the therapeutic alliance of the anti-antibody of CD 19 and mustargen
JP2018513149A5 (en)
JP2015517512A5 (en)
JP2018529672A5 (en)
NZ735052B2 (en) Therapeutic antibodies and their uses
NZ774326B2 (en) Therapeutic antibodies and their uses
NZ738208A (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
NZ738208B2 (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2027 BY THOMSON REUTERS

Effective date: 20260202